192 related articles for article (PubMed ID: 19067476)
1. Combination of sorafenib and intensity modulated radiotherapy for unresectable hepatocellular carcinoma.
Hsieh CH; Jeng KS; Lin CC; Chen CK; Liu CY; Lin CP; Tai HC; Wang CH; Shueng PW; Chen YJ
Clin Drug Investig; 2009; 29(1):65-71. PubMed ID: 19067476
[TBL] [Abstract][Full Text] [Related]
2. [Hepatocellular carcinoma - long-term treatable disease].
Fínek J
Klin Onkol; 2012; 25(4):287-9. PubMed ID: 22920170
[TBL] [Abstract][Full Text] [Related]
3. [Our experience of the treatment with sorafenib for unresectable hepatocellular carcinoma].
Ishizaki M; Kaibori M; Matsui K; Nakatake R; Matsushima H; Sakaguchi T; Kwon AH
Gan To Kagaku Ryoho; 2011 Nov; 38(12):2493-5. PubMed ID: 22202424
[TBL] [Abstract][Full Text] [Related]
4. Maintenance of Sorafenib following combined therapy of three-dimensional conformal radiation therapy/intensity-modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma: a phase I/II study.
Zhao JD; Liu J; Ren ZG; Gu K; Zhou ZH; Li WT; Chen Z; Xu ZY; Liu LM; Jiang GL
Radiat Oncol; 2010 Feb; 5():12. PubMed ID: 20149262
[TBL] [Abstract][Full Text] [Related]
5. The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma.
Cabrera R; Pannu DS; Caridi J; Firpi RJ; Soldevila-Pico C; Morelli G; Clark V; Suman A; George TJ; Nelson DR
Aliment Pharmacol Ther; 2011 Jul; 34(2):205-13. PubMed ID: 21605146
[TBL] [Abstract][Full Text] [Related]
6. Target therapy for hepatocellular carcinoma: is sorafenib for everybody?
Daniele B; Di Maio M
J Clin Gastroenterol; 2009; 43(5):389-90. PubMed ID: 19564813
[No Abstract] [Full Text] [Related]
7. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Cheng AL; Kang YK; Chen Z; Tsao CJ; Qin S; Kim JS; Luo R; Feng J; Ye S; Yang TS; Xu J; Sun Y; Liang H; Liu J; Wang J; Tak WY; Pan H; Burock K; Zou J; Voliotis D; Guan Z
Lancet Oncol; 2009 Jan; 10(1):25-34. PubMed ID: 19095497
[TBL] [Abstract][Full Text] [Related]
8. Long-term results of sorafenib in advanced-stage hepatocellular carcinoma: what can we learn from routine clinical practice?
Sacco R; Bargellini I; Ginanni B; Bertini M; Faggioni L; Federici G; Romano A; Bertoni M; Metrangolo S; Altomare E; Parisi G; Tumino E; Scaramuzzino A; Bresci G; Bartolozzi C
Expert Rev Anticancer Ther; 2012 Jul; 12(7):869-75. PubMed ID: 22845401
[TBL] [Abstract][Full Text] [Related]
9. [The outcome of chemotherapy by sorafenib in advanced hepatocellular carcinoma].
Amano R; Yamada N; Noda E; Kubo N; Tanaka H; Muguruma K; Takashima T; Yashiro M; Maeda K; Onoda N; Sawada T; Nakata B; Ohira M; Ishikawa T; Hirakawa K
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2676-8. PubMed ID: 21224677
[TBL] [Abstract][Full Text] [Related]
10. A long-lasting response to sorafenib treatment in an advanced hepatocellular carcinoma patient.
Di Lorenzo G; Imbimbo M; Leopardo D; Marciano R; Federico P; Buonerba C; Salvatore B; Marinelli A; Palmieri G
Int J Immunopathol Pharmacol; 2010; 23(3):951-4. PubMed ID: 20943068
[TBL] [Abstract][Full Text] [Related]
11. [Sorafenib for the treatment of HCC--the beginning of a new era in the treatment of HCC].
Greten TF; Manns MP; Malek N
Z Gastroenterol; 2009 Jan; 47(1):55-60. PubMed ID: 19156592
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of sorafenib in advanced hepatocellular carcinoma under daily practice conditions.
Welker MW; Lubomierski N; Gog C; Herrmann E; Engels K; Vogl TJ; Bechstein WO; Zeuzem S; Trojan J
J Chemother; 2010 Jun; 22(3):205-11. PubMed ID: 20566428
[TBL] [Abstract][Full Text] [Related]
13. Selection of patients with hepatocellular carcinoma for sorafenib.
Abou-Alfa GK
J Natl Compr Canc Netw; 2009 Apr; 7(4):397-403. PubMed ID: 19406040
[TBL] [Abstract][Full Text] [Related]
14. Invasive squamous cell carcinoma and sorafenib in a black patient.
Donaldson MR; Stetson CL; Smith JL
Arch Dermatol; 2011 Jan; 147(1):133-4. PubMed ID: 21242415
[No Abstract] [Full Text] [Related]
15. What is the indication for sorafenib in hepatocellular carcinoma? A clinical challenge.
Kim R; Byrne MT; Tan A; Aucejo F
Oncology (Williston Park); 2011 Mar; 25(3):283-91, 295. PubMed ID: 21548473
[TBL] [Abstract][Full Text] [Related]
16. Portal hemodynamic effects of sorafenib in patients with advanced hepatocellular carcinoma: a prospective cohort study.
Hidaka H; Nakazawa T; Kaneko T; Minamino T; Takada J; Tanaka Y; Okuwaki Y; Watanabe M; Shibuya A; Koizumi W
J Gastroenterol; 2012 Sep; 47(9):1030-5. PubMed ID: 22402773
[TBL] [Abstract][Full Text] [Related]
17. [Sorafenib in the treatment of hepatocellular carcinoma].
Suchánková G; Spicák J
Vnitr Lek; 2011 May; 57(5):485-90. PubMed ID: 21695929
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib.
Lee JH; Park JY; Kim DY; Ahn SH; Han KH; Seo HJ; Lee JD; Choi HJ
Liver Int; 2011 Sep; 31(8):1144-9. PubMed ID: 21745288
[TBL] [Abstract][Full Text] [Related]
19. [Therapeutic efficacy and prognostic factors of sorafenib treatment in patients with unresectable primary hepatocellular carcinoma].
Zhang L; Ren ZG; Gan YH; Wang YH; Zhang BH; Chen Y; Xie XY; Ge NL; Ye SL
Zhonghua Zhong Liu Za Zhi; 2010 Aug; 32(8):630-3. PubMed ID: 21122420
[TBL] [Abstract][Full Text] [Related]
20. Safe use of sorafenib in a patient undergoing salvage liver transplantation for recurrent hepatocellular carcinoma after hepatic resection.
Kim R; Menon N; Aucejo F
Med Oncol; 2011 Dec; 28(4):1044-7. PubMed ID: 20635167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
